AZURITY
LIVE

Serial Number

88439326

Owner

CutisPharma, Inc.

Attorney

Douglas R. Wolf

First Use Date

Aug 31, 2020

Filing Date

May 21, 2019

Add to watchlist:

No watchlists yet
View on USPTO

AZURITY Trademark

Serial Number: 88439326 • Registration: 6196161

AZURITY is a trademark filed by CutisPharma, Inc. on May 21, 2019. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently registered and active.

Owner Contact Info

CutisPharma, Inc.

Woburn, MA 01801

Entity Type: 03

AZURITY PHARMACEUTICALS, INC. (89 trademarks)

WOBURN, MA 01801

Entity Type: 03

Trademark Details

Filing Date

May 21, 2019

Registration Date

November 10, 2020

First Use Anywhere

August 31, 2020

First Use in Commerce

August 31, 2020

Published for Opposition

March 3, 2020

Goods & Services

Pharmaceutical preparations sold as a kit for use by pharmacists and physicians in creating compounded hormone replacement medicines, topical anti-inflammatory and ultrasound gels, pain and gastrointestinal disorders treatment medicines, and anti-inflammatory, antimicrobial, and antifungal treatment medicines; medicines for the treatment of cardiovascular diseases and disorders, colitis, muscle spasm, infectious diseases, acid-reflux disease, ulcer disease, and urological disorders; antibiotics; pharmaceutical products for the treatment of pain, thyroid disorders, gastrointestinal disorders, gastroesophageal disorders, inflammation, infections, fungal diseases and disorders, cardiovascular diseases and disorders, colitis, muscle spasm, attention deficit hyperactivity disorders, infectious diseases, acid-reflux disease, ulcer disease, and urological disorders having vancomycin, enalapril, lisinopril, and methotrexate as the active pharmaceutical ingredient; antacids; muscle relaxants; hormone replacement medicines; topical anti-inflammatory and ultrasound gels; pharmaceutical preparation for the treatment of pain, thyroid disorders, gastrointestinal disorders, gastroesophageal disorders, inflammation, infections, fungal diseases and disorders, cardiovascular diseases and disorders, colitis, muscle spasm, attention deficit hyperactivity disorders, infectious diseases, acid-reflux disease, ulcer disease, and urological disorders; pharmaceuticals for use in the treatment of cancer and autoimmune diseases and disorders, and for the treatment and prevention of renal, oncological, inflammatory, gastrointestinal, gastroesophageal, and cardio-vascular diseases and disorders

Filing History

TEAS SECTION 8 & 15 RECEIVED
Jun 3, 2026 E815
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Nov 10, 2025 REM1
ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
Mar 19, 2025 ASCK
REGISTERED-PRINCIPAL REGISTER
Nov 10, 2020 R.PR
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Oct 8, 2020 SUNA
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Oct 7, 2020 CNPR
STATEMENT OF USE PROCESSING COMPLETE
Oct 2, 2020 SUPC
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Oct 2, 2020 AITU
USE AMENDMENT FILED
Sep 17, 2020 IUAF
TEAS STATEMENT OF USE RECEIVED
Sep 17, 2020 EISU
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Apr 29, 2020 ASGN
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Apr 28, 2020 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Mar 3, 2020 NPUB
PUBLISHED FOR OPPOSITION
Mar 3, 2020 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Feb 12, 2020 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Jan 30, 2020 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jan 29, 2020 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jan 29, 2020 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jan 29, 2020 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Aug 9, 2019 GNRN
NON-FINAL ACTION E-MAILED
Aug 9, 2019 GNRT
NON-FINAL ACTION WRITTEN
Aug 9, 2019 CNRT
ASSIGNED TO EXAMINER
Aug 8, 2019 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jun 5, 2019 NWOS
NEW APPLICATION ENTERED
May 24, 2019 NWAP